883874-55-3Relevant academic research and scientific papers
Synthesis and evaluation of amides surrogates of dopamine D3 receptor ligands
Jean, Micka?l,Renault, Jacques,Levoin, Nicolas,Danvy, Denis,Calmels, Thierry,Berrebi-Bertrand, Isabelle,Robert, Philippe,Schwartz,Lecomte,Uriac, Philippe,Capet, Marc
scheme or table, p. 5376 - 5379 (2010/12/24)
Isosteric replacement of the amide function and modulation of the arylpiperazine moiety of known dopamine D3 receptor ligands led to potent and selective compounds. Enhanced bioavailability and preferential brain distribution make compound 6c a good candi
N-(4-(4-(2-halogenophenyl)piperazin-1-yl)butyl) substituted cinnamoyl amide derivatives as dopamine D2 and D3 receptor ligands
Saur, Oliver,Hackling, Anneke E.,Perachon, Sylvie,Schwartz, Jean-Charles,Sokoloff, Pierre,Stark, Holger
, p. 178 - 184 (2008/02/09)
A series of eight substituted N-(4-(4-(2-halogenophenyl)piperazin-1-yl) butyl)-3-phenylacryl amide derivatives have been synthesized and screened for binding affinities at dopamine hD2 and hD3 receptors. All compounds have shown high
3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands
-
Page/Page column 11, (2008/06/13)
The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders.
Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents
-
Page/Page column 10-11, (2008/06/13)
The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent.
